dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: inosine monophosphate dehydrogenase 1

Ligand: thioguanine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1966)
Primary target: yes
Median affinity:  -
Reference (Journal): Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites.
Published in: Curr Pharm Des

Ligand: thioguanine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1966)
Primary target: yes
Median affinity:  -
Reference (Journal): IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
Published in: Scand J Clin Lab Invest

Ligand: ribavirin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1985), EMA (1999)
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
Published in: Bioorg Med Chem

Ligand: mycophenolic acid (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid.
Published in: J Med Chem

Ligand: mycophenolate mofetil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: yes
Median affinity:  -
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: dihydrofolate reductase

Ligand: trimetrexate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1993)
Primary target: no
Median affinity: 7.889999866485596 pKi
Reference (Journal): 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Published in: J Med Chem

Ligand: pralatrexate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: yes
Median affinity: 7.349999904632568 pKi
Reference (Journal): Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.
Published in: Cancer Chemother Pharmacol

Ligand: pemetrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: yes
Median affinity: 8.149999618530273 pKi
Reference (Journal): Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
Published in: J Med Chem

Ligand: pemetrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: yes
Median affinity: 8.149999618530273 pKi
Reference (Journal): Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Published in: Adv Enzyme Regul

Ligand: methotrexate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1953), EMA (2016)
Primary target: yes
Median affinity: 8.920000076293945 pKi
Reference (Journal): 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Published in: J Med Chem

Ligand: iclaprim (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.110000133514404 pKi

Ligand: diflunisal (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity: 4.46999979019165 pKi
Reference (Journal): The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase
Published in: Journal of Medicinal Chemistry

Ligand: compound 9 [PMID: 15615544] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.470000267028809 pKi
Reference (Journal): Synthesis and in vitro antifolate activity of rotationally restricted aminopterin and methotrexate analogues.
Published in: J Med Chem
Target family: Nucleoside synthesis and metabolism (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum dihydroorotate dehydrogenase

Ligand: DSM421 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.28000020980835 pIC50
Reference (Journal): A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Published in: ACS Infect Dis
Target family: Nucleoside synthesis and metabolism (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum purine nucleoside phosphorylase

Ligand: quinine (Natural product)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (2005, as quinine sulfate, previous history unspecified)
Primary target: no
Median affinity: 6.860000133514404 pKi
Reference (Journal): Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay.
Published in: Sci Transl Med

Ligand: mefloquine (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1989), UK (1989)
Primary target: no
Median affinity: 5.230000019073486 pKi
Reference (Journal): Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay.
Published in: Sci Transl Med

Ligand: forodesine (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.220000267028809 pKi
Reference (Journal): Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum.
Published in: J Biol Chem

Ligand: forodesine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.460000038146973 pIC50
Reference (Journal): Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase.
Published in: J Biol Chem
Target family: Nucleotide turnover (type: enzyme)
Target: CTP synthase 1

Ligand: compound 27 [PMID: 36449304] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pIC50
Reference (Journal): Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.
Published in: J Med Chem
Target family: Nucleotide turnover (type: enzyme)
Target: dihydropyrimidine dehydrogenase

Ligand: RO0094889 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Published in: Bioorg Med Chem Lett
Target family: Nucleotide turnover (type: enzyme)
Target: CTP synthase 2

Ligand: compound 27 [PMID: 36449304] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.
Published in: J Med Chem

Ligand: compound 27 [PMID: 36449304] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.480000019073486 pIC50
Reference (Journal): Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.
Published in: J Med Chem

Ligand: compound 27 [PMID: 36449304] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.
Published in: J Med Chem
Target family: Nucleotide turnover (type: enzyme)
Target: CTP synthase 1

Ligand: compound 27 [PMID: 36449304] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.
Published in: J Med Chem

Ligand: compound 27 [PMID: 36449304] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.489999771118164 pIC50
Reference (Journal): Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.
Published in: J Med Chem
Target family: Numb-associated kinase (NAK) family (type: enzyme)
Target: BMP2 inducible kinase

Ligand: baricitinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2017), FDA (2018)
Primary target: no
Median affinity: 7.400000095367432 pKd
Reference (Journal): COVID-19: combining antiviral and anti-inflammatory treatments.
Published in: Lancet Infect Dis
Target family: Numb-associated kinase (NAK) family (type: enzyme)
Target: cyclin G associated kinase

Ligand: SB203580 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.869999885559082 pIC50

Ligand: baricitinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2017), FDA (2018)
Primary target: no
Median affinity: 6.869999885559082 pKd
Reference (Journal): COVID-19: combining antiviral and anti-inflammatory treatments.
Published in: Lancet Infect Dis
Target family: Numb-associated kinase (NAK) family (type: enzyme)
Target: BMP2 inducible kinase

Ligand: compound 6 [PMID: 34333981] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
Published in: J Med Chem

Ligand: compound 5m [PMID: 20483621] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Published in: Bioorg Med Chem

Ligand: compound 13 [PMID: 34333981] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
Published in: J Med Chem
Target family: Opioid receptors (type: gpcr)
Target: &mu; receptor

Ligand: CTAP (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pKi
Reference (Journal): Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Published in: NIDA Res Monogr
Target family: Opsin/rhodopsin kinases (type: enzyme)
Target: G protein-coupled receptor kinase 7

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.739999771118164 pIC50
Reference (Journal): Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Published in: J Med Chem
Target family: Opsin/rhodopsin kinases (type: enzyme)
Target: G protein-coupled receptor kinase 1

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.46999979019165 pIC50
Reference (Journal): Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Published in: J Med Chem
Target family: Orai channels (type: other_ic)
Target: Orai1

Ligand: CRAC channel inhibitor 1 [PMID: 26256403] (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel.
Published in: Acta Pharmacol Sin

Ligand: CRAC channel inhibitor 5b [PMID: 26256403] (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel.
Published in: Acta Pharmacol Sin

Ligand: GSK-7975A (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Patent): Pancreatitis treatment
Target family: Orai channels (type: other_ic)
Target: Orai2

Ligand: CM4620 (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.050000190734863 pIC50
Reference (Patent): Pancreatitis treatment

Ligand: GSK-7975A (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.840000152587891 pIC50
Reference (Patent): Pancreatitis treatment
Target family: Orai channels (type: other_ic)
Target: Orai1

Ligand: CM4620 (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.920000076293945 pIC50
Reference (Patent): Pancreatitis treatment

Ligand: compound 36 [PMID: 34843241] (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-<i>N</i>-(2'-methyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide. Structure-Activity Relationship and Preclinical Characterization.
Published in: J Med Chem
Target family: Orexin receptors (type: gpcr)
Target: OX<sub>1</sub> receptor

Ligand: [125I]orexin A (human, mouse, rat) (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells.
Published in: Cell Signal

Ligand: [125I]orexin A (human, mouse, rat) (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.
Published in: Cell

Ligand: [125I]orexin A (human, mouse, rat) (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery.
Published in: Br J Pharmacol

Ligand: [3H]-almorexant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
Published in: Mol Pharmacol
Target family: Organic anion transporters (OATs) (type: transporter)
Target: Organic anion transporter 4

Ligand: cefalotin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 6.699999809265137 pKi
Reference (Journal): Interaction of human organic anion transporters with various cephalosporin antibiotics.
Published in: Eur J Pharmacol
Target family: Organic anion transporters (OATs) (type: transporter)
Target: Organic anion transporter 1

Ligand: probenecid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1951)
Primary target: yes
Median affinity: 4.900000095367432 pIC50
Reference (Journal): Urate transport via human PAH transporter hOAT1 and its gene structure.
Published in: Kidney Int
Target family: Organic anion transporters (OATs) (type: transporter)
Target: Organic anion transporter 3

Ligand: cefalotin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Interaction of human organic anion transporters with various cephalosporin antibiotics.
Published in: Eur J Pharmacol

Ligand: NPT520-34 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pIC50
Reference (Journal): NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease.
Published in: Brain
Target family: Organic cation transporters (OCT) (type: transporter)
Target: Organic cation transporter 2

Ligand: decynium 22 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7 pKi
Reference (Journal): Cloning and characterization of two human polyspecific organic cation transporters.
Published in: DNA Cell Biol
Target family: Organic cation transporters (OCT) (type: transporter)
Target: Organic cation transporter 1

Ligand: clonidine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 6.260000228881836 pKi
Reference (Journal): Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Published in: J Pharmacol Exp Ther
Target family: Organic cation transporters (OCT) (type: transporter)
Target: Organic cation transporter 3

Ligand: disprocynium24 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pKi
Reference (Journal): Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.
Published in: Nat Neurosci
Target family: Other 7TM proteins (type: gpcr)
Target: <i>GPR143</i>

Ligand: levodopa (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1993), EMA (2003)
Median affinity:  -
Reference (Journal): L-DOPA is an endogenous ligand for OA1.
Published in: PLoS Biol
Target family: Other antimalarial targets (type: other_protein)
Target: Plasmodium falciparum acetyl-CoA synthetase

Ligand: MMV693183 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.619999885559082 pIC50
Reference (Patent): Pantothenamide analogues
Target family: Other antimalarial targets (type: other_protein)
Target: Plasmodium falciparum cleavage and polyadenylation specificity factor subunit 3

Ligand: AN3661 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.409999847412109 pIC50
Reference (Journal): A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Published in: Nat Commun

Ligand: AN3661 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.25 pIC50
Reference (Journal): A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Published in: Nat Commun

Ligand: AN3661 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Published in: Nat Commun

Ligand: AN3661 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pIC50
Reference (Journal): A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Published in: Nat Commun
Target family: Other antimalarial targets (type: other_protein)
Target: Plasmodium falciparum GPI-anchored wall transfer protein 1

Ligand: compound VII [WO2021149692A1] (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Patent): Novel antimalarial agent containing heterocyclic compound
Target family: Other antimalarial targets (type: other_protein)
Target: Plasmodium falciparum cleavage and polyadenylation specificity factor subunit 3

Ligand: AN3661 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Published in: Nat Commun
Target family: Other antimalarial targets (type: other_protein)
Target: Plasmodium falciparum GPI-anchored wall transfer protein 1

Ligand: compound VII [WO2021149692A1] (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.389999866485596 pIC50
Reference (Patent): Novel antimalarial agent containing heterocyclic compound
Target family: Other antimalarial targets (type: other_protein)
Target: Plasmodium falciparum acetyl-CoA synthetase

Ligand: MMV689258 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in <i>Plasmodium falciparum</i>.
Published in: Sci Transl Med

Ligand: MMV693183 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
Published in: bioRxiv

Ligand: MMV693183 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Patent): Pantothenamide analogues